Retrogenix SARS-CoV-2 comprehensive receptor profiling, and therapeutic developments

The Retrogenix platform has been used to advance therapeutic developments for COVID-19, such as: identifying potential human plasma membrane therapeutic targets for viral cell entry, and safety screening COVID-19 biotherapeutics.

Identification of such receptors, and safety screening COVID-19 therapies, will help to progress therapeutic developments.

How can our cell microarray platform advance therapeutic development for COVID-19?

Retrogenix’s unique cell microarray technology provides a fast, accurate solution for discovering the human cell surface and secreted protein targets of antibodies, proteins, CAR-T cells, viruses, and small molecules.

Our unique tool uses proprietary arrays of expression vectors – encoding over 6,200 human plasma membrane, tethered secreted, and heterodimer proteins – spotted onto slides. Human cells grown over the top become reverse-transfected, resulting in cell surface expression of each respective protein at distinct slide locations. The test molecule is applied and specific binding analysed and confirmed using an appropriate detection system.

Jo Soden, Co-founder and Director at Retrogenix, says:

By screening against our unique library of human cell surface proteins, Retrogenix has previously been highly successful in identifying viral receptors. Using the same technology, we now have the perfect opportunity to search for new receptors for COVID-19.

A positive find could have significant consequences in the search for treatments.

See below to find out how to stay up to date with this research.

Stay informed as further information is released regarding this COVID-19 research with the option that suits you best:

Or please feel free to get in touch with us directly using the form.

 

Retrogenix provides key IND-enabling specificity data, with a growing interest amongst top biopharma companies as a replacement to tissue cross-reactivity studies, as well as generating data to aid lead selection discussions. Learn more:

Stay informed on this research

    I would like to thank you very much for the great and very timely work including this report which will be key data for our submission to the regulatory authorities.
    Marcel Walser, PhD, Senior Director Research, Molecular Partners
    Simcere logo
    Aveo Oncology - The Human Response
    Theraclone Sciences
    BioInvent
    AstraZeneca
    Bluebird Bio
    glycotope_logo
    The Center for Infectious Disease Research
    Compugen Logo
    Sanofi Logo
    The University of Copenhagen
    Lund University
    MedImmune
    NIH - National Institutes of Health
    The University of Pennsylvania
    Scripps Florida - The Scripps Research Institute
    Peptinnovate Ltd - Unlocking Nature's Potential
    The University of Sheffield
    Capella Bioscience Logo
    Unum Theraputics Logo
    Celyad Logo
    Genmab Logo
    Molecular Partners Logo
    NanoMab Logo